701 PIKE STREET, SEATTLE, WA
Director Appointment - Robert Meyer Joins Avalyn Pharma Board
Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma Expands Lease with CRISPR Therapeutics by 4,934 Sq Ft
Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis
Reports First Quarter 2026 Financial Results and Recent Business Highlights
News, Articles of Incorporation, Bylaws
Q2
Q1
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Registration of Securities
Amended Registration Statement for Securities
S-1
No filings found
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Schedule 13D - Ownership Report